Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

Open access
Rea, Delphine, Henry, Guylaine, Khaznadar, Zena, Etienne, Gabriel, Guilhot, François, Nicolini, Franck, Guilhot, Joelle, Rousselot, Philippe, Huguet, Françoise, Legros, Laurence, Gardembas, Martine, Dubruille, Viviane, Guerci-Bresler, Agnès, Charbonnier, Aude, Maloisel, Frédéric, Ianotto, Jean-Christophe, Villemagne, Bruno, Mahon, François-Xavier, Moins-Teisserenc, Hélène, Dulphy, Nicolas, Toubert, Antoine · 2017 · Haematologica

Abstract

Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered regarding the biological basis of molecular relapse after imatinib cessation. In IMMUNOSTIM, we monitored 51 patients from the French Stop IMatinib trial for peripheral blood T cells and natural killer cells. Molecular relapse-free survival at 24 months was 45.1% (95% CI: 31.44%–58.75%). At the time of imatinib discontinuation, non-relapsing patients had significantly higher numbers of natural killer cells of the cytotoxic CD56dim subset than had relapsing patients, while CD56bright natural killer cells, T cells and their subsets did not differ significantly. Furthermore, the CD56dim natural killer-cell count was an independent prognostic factor of molecular-relapse free survival in a multivariate analysis. However, expression of natural killer-cell activating receptors, BCR-ABL1+ leukemia cell line K562-specific degranulation and cytokine-induced interferon-gamma secretion were decreased in non-relapsing and relapsing patients as compared with healthy individuals. After imatinib cessation, the natural killer-cell count increased significantly and stayed higher in non-relapsing patients than in relapsing patients, while receptor expression and functional properties remained unchanged. Altogether, our results suggest that natural killer cells may play a role in controlling leukemia-initiating cells at the origin of relapse after imatinib cessation, provided that these cells are numerous enough to compensate for their functional defects. Further research will decipher mechanisms underlying functional differences between natural killer cells from patients and healthy individuals and evaluate the potential interest of immunostimulatory approaches in tyrosine kinase inhibitor discontinuation strategies. (ClinicalTrial.gov Identifier NCT00478985)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2017.165001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 161

Metadata

Authors
Rea, D., Henry, G., Khaznadar, Z., Etienne, G., Guilhot, F., Nicolini, F., Guilhot, J., Rousselot, P., Huguet, F., Legros, L., Gardembas, M., Dubruille, V., Guerci-Bresler, A., Charbonnier, A., Maloisel, F., Ianotto, J.-C., Villemagne, B., Mahon, F.-X., Moins-Teisserenc, H., Dulphy, N., & Toubert, A.
Venue
Haematologica
Published
2017-05-18
Volume
102
Issue
8
Pages
1368-1377
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W2615706081
Cited by
161
References
2
FWCI
10.86
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. https://app.cochat.ai/papers/10.3324/haematol.2017.165001
The paper
Rea, D., Henry, G., Khaznadar, Z., Etienne, G., Guilhot, F., Nicolini, F., Guilhot, J., Rousselot, P., Huguet, F., Legros, L., Gardembas, M., Dubruille, V., Guerci-Bresler, A., Charbonnier, A., Maloisel, F., Ianotto, J.-C., Villemagne, B., Mahon, F.-X., Moins-Teisserenc, H., . . . Toubert, A. (2017). Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. https://doi.org/10.3324/haematol.2017.165001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.